Spots Global Cancer Trial Database for Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma
Official Title: Phase I/II Trial for Vaccine Therapy With Dendritic Cells - Transfected With hTERT-, Survivin- and Tumor Cell Derived mRNA + ex Vivo T Cell Expansion and Reinfusion in Patients With Metastatic Malignant Melanoma
Study ID: NCT00961844
Conditions
Study Description
Brief Summary: In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell expansion after lymphodepletion for the patients who show an immune response.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Norwegian Radium Hospital, Department of Clinical Cancer Research, Oslo, Montebello, Norway
Contact Details
Name: Steinar Aamdal, M.D PhD Prof
Affiliation: Oslo University Hospital - Norwegian Radium Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
